3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
6
Unknown
3
Terminated
2
Completed
2
Withdrawn
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
438
Carboplatin
322
Nivolumab
286
Cyclophosphamide
280
Specimen Handling
257
Cisplatin
252
Paclitaxel
249
Magnetic Resonance Spectroscopy
248
Radiotherapy
217
Gemcitabine
180
Dexamethasone
180
Biopsy
177
durvalumab
167
atezolizumab
148
Rituximab
138
Lenalidomide
134
Doxorubicin
134
Docetaxel
130
Bevacizumab
129
Ipilimumab
125
Radiation
118
Capecitabine
117
Pemetrexed
113
Oxaliplatin
112
Etoposide
111
Radiosurgery
109
venetoclax
108
Fluorouracil
108
fludarabine
106
Prednisone
97
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Interventional
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled